talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. the company was founded on technology discovered and developed by dr. suzanne ildstad and operates its own cell processing facility in louisville. talaris is backed by leading life sciences investors blackstone life sciences, longitude capital and qiming venture partners usa.
Company profile
Ticker
TRML
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Talaris Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Tourmaline Sub, Inc. ...
TRML stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
S-8
Registration of securities for employees
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
19 Mar 24
8-K
Other Events
26 Jan 24
424B5
Prospectus supplement for primary offering
26 Jan 24
424B5
Prospectus supplement for primary offering
24 Jan 24
8-K
Results of Operations and Financial Condition
24 Jan 24
Latest ownership filings
SC 13G/A
PFIZER INC
15 Mar 24
SC 13G/A
Hydra LLC
14 Feb 24
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
Blackstone Holdings II L.P.
9 Feb 24
SC 13G
TCG Crossover GP I, LLC
9 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
MARK MCDADE
31 Jan 24
4
CLAY B SIEGALL
15 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 67.08 mm | 67.08 mm | 67.08 mm | 67.08 mm | 67.08 mm | 67.08 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.98 mm | 5.78 mm | 2.51 mm | 4.42 mm |
Cash used (since last report) | n/a | n/a | 20.48 mm | 39.74 mm | 17.24 mm | 30.39 mm |
Cash remaining | n/a | n/a | 46.60 mm | 27.34 mm | 49.84 mm | 36.70 mm |
Runway (months of cash) | n/a | n/a | 15.7 | 4.7 | 19.9 | 8.3 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 62 |
Opened positions | 22 |
Closed positions | 16 |
Increased positions | 11 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 75.68 bn |
Total shares | 41.45 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BX Blackstone | 8.09 mm | $24.59 bn |
Blackstone Holdings II | 8.09 mm | $123.69 mm |
Longitude Capital Partners III | 3.22 mm | $45.64 mm |
Qiming U.S. Ventures Management | 2.93 mm | $8.92 bn |
Ra Capital Management | 2.33 mm | $7.09 bn |
BML Investment Partners | 2.09 mm | $4.49 mm |
BML Capital Management | 2.00 mm | $6.08 bn |
Qiming U.S. Healthcare GP II | 1.83 mm | $25.96 mm |
Nantahala Capital Management | 1.45 mm | $4.41 bn |
Vanguard | 1.04 mm | $3.16 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jan 24 | Mcdade Mark | Common Stock | Buy | Acquire P | Yes | No | 32.5 | 100,000 | 3.25 mm | 448,431 |
13 Dec 23 | Siegall Clay B | Stock Option Common Stock | Grant | Acquire A | No | No | 18.55 | 20,000 | 371.00 k | 20,000 |
17 Nov 23 | Parvinder Thiara | Common Stock | Buy | Acquire P | No | No | 17.31 | 1,000 | 17.31 k | 83,782 |
17 Nov 23 | Sandeep Chidambar Kulkarni | Common Stock | Buy | Acquire P | No | No | 16.99 | 4,000 | 67.96 k | 729,735 |
News
Truist Securities Reiterates Buy on Tourmaline Bio, Maintains $74 Price Target
25 Mar 24
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
21 Mar 24
12 Health Care Stocks Moving In Thursday's Intraday Session
21 Mar 24
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
21 Mar 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Mar 24
Press releases
Tourmaline Bio to Present at Upcoming Investor Conferences
27 Feb 24
Thinking about buying stock in Digital Brands Group, Tourmaline Bio, Crown Electrokinetics, Datadog, or UiPath?
14 Feb 24
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
29 Jan 24